Welcome to our dedicated page for Teva Pharm news (Ticker: TEVA), a resource for investors and traders seeking the latest updates and insights on Teva Pharm stock.
News about Teva Pharmaceutical Industries Limited (TEVA) focuses on its transformation into an innovative biopharmaceutical company, its generics and biosimilars franchise, and developments across neuroscience and immunology. Company announcements highlight progress on its Pivot to Growth strategy, including updates on branded medicines such as AUSTEDO, AJOVY and UZEDY, as well as late-stage pipeline assets.
Recent news includes clinical and regulatory milestones for AJOVY (fremanezumab-vfrm), where Phase 3 SPACE trial results in children and adolescents with episodic migraine were published in the New England Journal of Medicine. These data supported U.S. FDA approval for preventive treatment of episodic migraine in pediatric patients who meet specified criteria, adding to AJOVY’s existing indication in adults. News items provide details on trial design, efficacy outcomes, and safety profile.
Investors and followers of TEVA can also find updates on pipeline programs such as olanzapine extended-release injectable suspension (TEV-'749) for schizophrenia and the anti‑IL‑15 antibody TEV-'408 for vitiligo and celiac disease, including regulatory submissions and funding agreements. Teva’s news flow covers biosimilar approvals and collaborations, such as European Commission approvals for denosumab biosimilars PONLIMSI and DEGEVMA and the U.S. settlement and license agreement for AVT06, a proposed biosimilar to Eylea.
In addition, TEVA news features financial and capital markets events, including rating agency actions, amendments to credit facilities, quarterly earnings release dates, conference call schedules, and participation in major healthcare conferences. This mix of clinical, regulatory, strategic and financial updates makes the TEVA news page a central resource for tracking how Teva’s generics base, innovative pipeline and biosimilars portfolio contribute to its stated Pivot to Growth strategy. Users interested in TEVA stock can monitor this page for ongoing disclosures that may inform their understanding of the company’s operations and strategic direction.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has announced upcoming presentations by its executive management team at two major healthcare conferences in June 2025. At the Jefferies Global Healthcare Conference on June 4, EVP U.S. Commercial Chris Fox and EVP Global R&D and Chief Medical Officer Dr. Eric Hughes will present at 9:20 am ET. At the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, President & CEO Richard Francis will present at 8:00 am ET. Live webcasts will be available on Teva's Investor Relations website, with archived versions accessible within 24 hours after each presentation.
Teva Pharmaceuticals (TEVA) has received a credit rating upgrade from Fitch Ratings Agency to BB+ from BB, with a stable outlook. The upgrade follows a recent rating improvement from Moody's and reflects Teva's successful debt reduction efforts and improved financial flexibility. Fitch's report highlights expected revenue growth from key products AUSTEDO and AJOVY, along with the company's promising biosimilar pipeline. The agency also noted that Teva's focus on optimizing external spend, resource allocation, and organizational modernization is anticipated to boost operating margins.